Sonus, Abbott deal

The companies signed an agreement for EchoGen, SNUS's fluorocarbon-based ultrasound contrast agent, expanding Abbott's licensed territory to include Europe, Latin America, Canada, the Middle East, Africa, and certain Pacific Rim countries.

SNUS has primary responsibility for clinical development and regulatory affairs for EchoGen in Europe. Abbott is responsible for international sales, and all clinical development and regulatory affairs outside the EC. SNUS retains co-promotion rights. ...